Auto-generated: January 25 2020 08:34 PM GMT

411
Stars
Star This?

Source: DGNews  |  Posted 9 years ago

FDA Restricts Access to Rosiglitazone, EMEA Recommends Suspension

ROCKVILLE, Md -- September 23, 2010 -- The US Food and Drug Administration
(FDA) announced that it will significantly restrict the use of the diabetes
drug rosiglitazone (Avandia) to patients with type 2 diabetes who cannot
control their diabetes on other medications.

These new restrictions are in response to data that suggest an elevated risk of
cardiovascular events, such as heart attack and stroke, in patients treated
with rosiglitazone.

On July 14, 2010, the FDA Advisory Panel voted to keep rosiglitazone on the
market despite concerns over associated heart risks -- 20 members voted in
favour, while 12 members voted to recommend that the FDA withdraw the drug.

Today, the European Medicines Agency (EMEA) recommended the suspension of the
marketing authorisations for rosiglitazone-containing anti-diabetes medications
in Europe (Avandia, Avandamet, and Avaglim). These medicines will stop being
available in Europe within the next few months. Physicians should stop
prescribing rosiglitazone-containing medicines.

The current review of rosiglitazone by the Agency’s Committee for Medicinal
Products for Human Use (CHMP) was initiated on July 9, 2010, following the
availability of new studies questioning the cardiovascular safety of the
medicine.

Data from clinical trials, observational studies, and meta-analyses of existing
studies that have become available over the last 3 years have suggested a
possibly increased risk of ischaemic heart disease associated with the use of
rosiglitazone. Further restrictions on the use of these medicines in patients
with ischaemic heart disease were introduced. The availability of recent
studies has added to the knowledge about rosiglitazone and overall, the
accumulated data support an increased cardiovascular risk of rosiglitazone. In
view of the restrictions already in place on the use of rosiglitazone, the
Committee could not identify additional measures that would reduce the
cardiovascular risk.

The Committee therefore concluded that the benefits of rosiglitazone no longer
outweigh its risks and recommended the suspension of the marketing
authorisation of the medicines.

The suspension will remain in place unless the marketing authorisation holder
can provide convincing data to identify a group of patients in whom the
benefits of the medicines outweigh their risks.

The Committee’s recommendation has now been forwarded to the European
Commission for the adoption of a legally binding decision.

SOURCE: US Food and Drug Administration and the European Medicines Agency

411
Stars
Star This?  Yes / No
 
Sign InSign In
inst val